British Columbia-based AI precision biotechnology company Gandeeva Therapeutics has raised USD 40 million in a Series A funding round led by Lux Capital and Leaps by Bayer (the impact investment arm of Bayer AG). Other investors including Obvious Ventures and Amgen Ventures also participated in the round.
The proceeds will be injected into advancing the company’s cryogenic electron microscopy (cryo-EM) platform by incorporating AI/ML tools to accelerate the identification of novel drug targets.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.